Impact of Surgical Technique on Outcomes in Younger Patients with Advanced Breast CancerSurgery type does not affect survival for younger breast cancer patients

This secondary analysis of the I-SPY2 clinical trial evaluates the impact of surgical intervention on outcomes in a large cohort of women diagnosed with advanced breast cancer. The study specifically focuses on the distinction between breast-conserving surgery and mastectomy in patients under the age of 45. By analyzing a substantial sample size of 1,737 patients, the researchers aimed to determine if younger age served as a significant driver for surgical selection or if it influenced long-term survival outcomes.

Data collection revealed a significant disparity in surgical choices based on age. Patients aged 45 and younger were significantly less likely to undergo breast-conserving surgery compared to their older counterparts. Specifically, the rate of breast-conserving surgery was 36.8% in the younger cohort versus 48.5% in the older cohort. This suggests that while clinical practice may lean toward more extensive surgery for younger patients, the underlying biological drivers of the disease may not necessitate such a distinction in terms of ultimate outcomes.

Regarding primary endpoints, the analysis focused on overall survival (OS) and locoregural recurrence-free interval. For the cohort of patients aged 45 and younger, the data indicated that the type of surgery performed—whether breast-conserving or mastectomy—had no statistically significant association with overall survival. This is a critical finding for clinicians managing younger patients, as it suggests that the choice of surgical technique does not dictate the primary survival metric in this specific demographic.

Furthermore, the locoregional recurrence-free interval showed no significant association with the type of surgery performed in the younger patient group. This suggests that the local control provided by mastectomy, while often preferred in younger patients to ensure local clearance, did not provide a measurable survival advantage over breast-conserving techniques in the context of this specific study's parameters. The findings provide a nuanced view of surgical decision-making.

From a clinical perspective, these results suggest that young age alone should not be the sole determinant for choosing a mastectomy over breast-conserving surgery following neoadjuvant systemic therapy. While surgical decisions are often influenced by patient preference and local control concerns, the data indicates that for the primary endpoint of survival, the surgical method did not create a significant divergence in outcomes for the younger population. However, it is important to note that this was a secondary analysis of existing clinical trial data. While the sample size was robust, the study provides an association rather than a definitive proof of surgical equivalence. Clinicians should consider these findings as a component of a broader multidisciplinary discussion regarding the management of advanced breast cancer in younger women, balancing local control, patient preference, and systemic treatment efficacy.